CAR T

Beatriz C Oliveira1, Saaurav Bari1, J Joseph Melenhorst1

  • 1Cell Therapy & Immuno-Engineering Program, Center for Immunotherapy and Precision Immuno-Oncology, Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44016, USA.

Cancers
|February 13, 2025
PubMed
概括

化学抗原受体 (CAR) T细胞疗法在治疗慢性淋巴细胞白血病 (CLL) 等B细胞癌方面显示出有前途. 载体整合部位和基因中断,如TET2突变,显著影响CAR T细胞功效和患者的结果.